End-of-life cost for lung cancer patients in Greece: a hospital-based retrospective study

Kokkotou, E.; Stefanou, Garyfallia; Syrigos, Nikolaos; Gourzoulidis, George; Ntalakou, Eleutheria; Apostolopoulou, Anna; Charpidou, Andriani; Kourlaba, Georgia

doi:10.2217/cer-2020-0167

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The end-of-life care cost was directly extracted from a recent Greek retrospective study. 27 A one-time terminal care cost of €7655 was considered in the model, including expenses for supporting patients during terminal stage by providing them the comfort needed (Table 2). This was applied on transition to the death health state.…”

Section: Journal Of Health Economics and Outcomes Researchmentioning

confidence: 99%

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

Gourzoulidis¹,

Zisimopoulou

Boubouchairopoulou

et al. 2022

JHEOR

Self Cite

View full text Add to dashboard Cite

Background: Non-small cell lung cancer (NSCLC), which accounts for about 80%-85% of lung cancer cases, is a leading cause of cancer-related death worldwide. Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with advanced, ALK-positive NSCLC previously treated with at least one second-generation ALK tyrosine kinase inhibitor. Objective: The present study assessed the cost-effectiveness of lorlatinib vs pemetrexed with platinum combination of carboplatin or cisplatin (P-ChT) in Greece. Methods: A partitioned survival model with 3 health states, referring to pre-progression, progressed disease, and death, was locally adapted from a Greek payer perspective over a lifetime horizon. Clinical and safety data and utility values applied in the model were extracted from the literature. A matching-adjusted indirect comparison of lorlatinib and P-ChT was performed. Only direct medical costs (€) from 2020 were included in the analysis. Primary outcomes were patient life years (LYs), quality-adjusted life years (QALYs), total costs, and incremental cost-effectiveness ratios per QALY and LY gained. All future outcomes were discounted at 3.5% per annum. A probabilistic sensitivity analysis was conducted to account for model uncertainty. Results: The analysis showed that, over a lifetime horizon, the estimated total costs of lorlatinib and P-ChT were €81 754 and €12 343, respectively. Lorlatinib was more effective than P-ChT with 2.4 and 1.5 more LYs and QALYs gained, respectively. The generated incremental cost-effectiveness ratios of lorlatinib compared with P-ChT were €28 613 per LY gained and €46 102 per QALY gained. Probabilistic sensitivity analysis confirmed the deterministic results. Conclusion: The present analysis suggests that lorlatinib may be considered as a cost-effective option compared with P-ChT in Greece for the treatment of patients with advanced, ALK-positive NSCLC whose disease has progressed after at least one second-generation ALK tyrosine kinase inhibitor. In addition, this option addresses a significant unmet medical need.

show abstract

Section: Journal Of Health Economics and Outcomes Researchmentioning

confidence: 99%

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

Gourzoulidis¹,

Zisimopoulou

Boubouchairopoulou

et al. 2022

JHEOR

Self Cite

View full text Add to dashboard Cite

show abstract

Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece

Gourzoulidis,

Zisimopoulou,

Liavas

et al. 2023

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

End-of-Life Costs in Cancer Patients: A Systematic Review

Ito Süffert,

Mantese,

Meira

et al. 2024

Am J Hosp Palliat Care

View full text Add to dashboard Cite

Objectives Identify the costs of an oncology patient at the end of life. Methods A systematic literature review was conducted by screening Embase, PubMed and Lilacs databases, including all studies evaluating end-of-life care costs for cancer patients up to March 2024. The review writing followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The quality of the included studies was assessed using the Drummond checklist. The protocol is available at PROSPERO CRD42023403186. Results A total of 733 studies were retrieved, and 43 were considered eligible. Among the studies analyzed, 41,86% included all types of neoplasms, 18.60% of lung neoplasm, All articles performed direct cost analysis, and 9.30% also performed indirect cost analysis. No study evaluated intangible costs, and most presented the macrocosting methodology from the payer’s perspective. The articles included in this review presented significant heterogeneity related to populations, diagnoses, periods considered for evaluation of end-of-life care, and cost analyses. Most of the studies were from a payer perspective (74,41%) and based on macrocosting methodologies (81,39%), which limit the use of the information to evaluate variabilities in the consumption of resources. Conclusions Considering the complexity of end-of-life care and the need for consistent data on costs in this period, new studies, mainly in low- and middle-income countries with approaches to indirect and intangible costs, with a societal perspective, are important for public policies of health in accordance with the trend of transforming value-based care, allowing the health care system to create more value for patients and their families.

show abstract

End-of-life cost for lung cancer patients in Greece: a hospital-based retrospective study

Cited by 3 publications

References 21 publications

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece

End-of-Life Costs in Cancer Patients: A Systematic Review

Contact Info

Product

Resources

About